The animal measurements
Bone growth and weight preservation
Length, mineral content, density and body weight give these animal experiments several different meanings of “growth.”
Bone length in female rats
In adult female Sprague-Dawley rats, ipamorelin increased the rate of longitudinal bone growth in a dose-dependent way. The vehicle group’s rate was 42 micrometres per day; the highest-dose group’s was 52 micrometres per day. This was a 15-day experiment.
The same study reported no change in total IGF-1, IGF-binding proteins or bone turnover markers. IGF-1 is insulin-like growth factor 1, a signal often discussed alongside growth hormone. Here a measured skeletal change appeared without a measurable change in those systemic markers.
Those results resist the neat story in which every stage of a hormone pathway rises together. The authors’ reported finding concerns longitudinal growth in those rats; a claim about human height or fracture prevention would require a different experiment.
I’m still curious about that mismatch. A narrow animal paper can leave a surprisingly awkward question.
Mineral content and bone size
A separate study in female Sprague-Dawley rats ran for 12 weeks. Body weight and total tibial and vertebral bone mineral content increased with ipamorelin, while cortical volumetric bone mineral density was unchanged. The reported interpretation was skeletal expansion through larger bone dimensions.
More mineral in a larger bone and a higher concentration of mineral describe different changes. The distinction is quite tangible if size and concentration are considered separately. In this experiment, content rose alongside skeletal growth while the measured cortical volumetric density stayed steady.
“Better bones” is a phrase I distrust: it compresses those measurements into a single flattering verdict. This study earns a more specific description. It supplies animal evidence about growth and mineral content, with the unchanged density measurement still attached.
A human claim about stronger bones would also need outcomes suited to that claim. The rat results are interesting on their own terms; borrowing a human benefit would make them harder to understand.
Weight loss in ferrets
The direction of the desired weight change depended on the problem. In a 2024 ferret experiment involving cisplatin, ipamorelin reduced chemotherapy-associated body-weight loss by approximately 24% on the last day of the delayed phase, 48–72 hours. It had no anti-emetic effect in either the acute or delayed phase: vomiting was a separate outcome, and that outcome did not improve.
The paired observations make the paper memorable to me. Weight preservation and relief from vomiting are easy to bundle into a general picture of recovery; the experiment separated them and produced different answers.
This is evidence from ferrets exposed to cisplatin. Its ambition was protection against weight loss in that model. Human weight control is far beyond the question this ferret experiment tested. The specific result is already substantial enough to discuss, including the failed anti-emetic ambition.
The meal trial is the human clinical story in this collection. It gives another answer to another question about eating and recovery.